Home

Search Abstracts

Browse Sessions

Program Committee

Conference Webcasts

Contact Us

---

Session 50   Poster Abstracts Vaccine Immunogenicity Wednesday, 1:30 - 3:30 pm Poster Hall

266	Development of a DNA Vaccine Designed to Induce Cytotoxic T Lymphocyte Responses to Multiple Conserved Epitopes in HIV-1 B Livingston*1, D McKinney1, M Anders2, S MaWhinney2, J Forster2, M Newman1, and C Wilson2 1Epimmune, San Diego, CA, USA and 2Univ. of Colorado Hlth. Sci. Ctr., Denver, USA
267	Relative Efficacy of SHIV 89.6 Live Virus and DNA Provirus Vaccines M Busch*1,2, K Abel1,2, L Fritts1, D Lu1, J D Lifson3, and C Miller1,2 1California Natl. Primate Res. Ctr., Davis, USA; 2Ctr. for Comparative Med., Univ. of California, Davis, USA; and 3NCI-FCRDC, NIH, DHHS, MD, USA
268	Improved Presentations of Envelope Immunogens Derived From Subtypes B and C HIV-1 Provide Increased Breadth of Neutralizing Antibody Responses S W Barnett*1, I Srivastava1, L Stamatatos2, Y Lian1, E Kan1, Y Sun1, D Montefiori3, M Robert-Guroff4, S Engelbrecht5, E Janse van Rensburg5, J Ulmer1, and J Donnelly1 1Chiron Corp., Emeryville, CA, USA; 2Seattle BioMed. Res. Inst., WA, USA; 3Duke Univ., Durham, NC, USA; 4NCI, NIH, DHHS, Bethesda, MD, USA; and 5Univ. of Stellenbosch, Tygerberg, South Africa
269	Expression and Immunogenicity of Novel HIV-1 Subtype C Vaccine Candidates J zur Megede*1, G Otten1, B Doe1, H Liu1, T Scriba2, E van Rensburg2, J Ulmer1, J Donnelly1, and S Barnett1 1Chiron Corp., Emeryville, CA, USA and 2Univ. of Stellenbosch, Tygerberg, South Africa
270	Neutralizing Antibody Responses Induced in Rhesus Macaques Using Different DNA Delivery Technologies as Prime and o-gp140deltaDV2 SF162 as Boost E Kan*1, G Otten1, Y Sun1, D Montefiore2, D O'Hagan1, M Singh1, J Donnelly1, J Ulmer1, S Barnett1, and I Srivastava1 1Chiron Corp., Emeryville, CA, USA and 2Duke Univ. Med. Ctr., Durham, NC, USA
271	Neonatal Vaccination Provides Long-term Protection of Macaques against Oral SIV Exposure M Marthas*1, K Van Rompay1, P Earl2, and J Tartaglia3 1Univ. of California, Davis, USA; 2NIAID, NIH, DHHS, Bethesda, MD, USA; and 3Aventis-Pasteur, Toronto, Canada
272	Effect of SIV Lipopeptide Vaccination on Survival of Macaques: Major Role of CTL Responses on Delaying Onset of AIDS Z Coutsinos*1, L Mortara1, A Beauchet1, P Villefroy1, H Gras-Masse2, A Venet1, J P Levy1, J G Guillet1, and I Bourgault-Villada1 1Paris, France and 2Lille, France
273	Env-CD4 Complexes Induce Neutralizing Antibodies Against Heterologous Primary HIV-1 Isolates I Srivastava*1, V Sharma1, E Kan1, C Vita2, L Martin2, Y Sun1, R Deck1, J Ulmer1, and S Barnett1 1Chiron Corp., Emeryville, CA, USA and 2CEA, Scalay, France
274	Potential Correlation of Structural Characterization and Immune Responses of Novel HIV Envelope Glycoproteins V A Sharma*, E Kan, Y Sun, S Barnett, J Ulmer, and I K Srivastava Chiron Corp., Emeryville, CA, USA
275	Purification, Characterization and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from TV1, an R5-Tropic Subtype C HIV-1 Isolate I Srivastava*1, E Kan1, V Sharma1, L Stamatatos2, Y Lian1, S Hilt1, K Matsuoka1, M Wininger1, Y Sun1, S Engelbrecht3, E van Ransberg3, J Donnelly1, J Ulmer1, and S Barnett1 1Chiron Corp., Emeryville, CA, USA; 2Seattle BioMed. Res. Inst., WA, USA; and 3Tygerberg Hosp., Univ. of Stellenbosch, South Africa
276	Allo-immunization with Mamu-A*01 and DRw201 Vaccine Failed to Protect Rhesus Macaque from Infection of SIVmac239 Derived from Mamu-A*01 and DRw201 Positive PBMC Y Guan*1, M Luscher2, E Rakasz3, D Watkins3, T Rustam1, N Khanna1, M Candido1, J Tartaglia4, D Burton5, and K MacDonald1 1Mount Sinai Hosp. and Univ. of Toronto, Toronto, Canada; 2Univ. Hlth. Network and Univ. of Toronto, Canada; 3Wisconsin Regional Primate Ctr., Madison, USA; 4Aventis Pasteur, Toronto, Canada; and 5Scripps Res. Inst., La Jolla, CA, USA
277	Therapeutic Immunization of SIVmac239-infected Rhesus Macaques, Using Inactivated SIV Virions with Intact Functional Envelope Glycoproteins J Lifson*1, M Piatak, Jr1, J Bess Jr1, F Yuan1, D Schneider1, A Cline1, V Coalter1, B Poore1, E Raz2, D Richman2, G Van Nest3, N Bischofberger4, J Hoxie5, M Pope6, and L Arthur1 1SAIC-Frederick, Inc., MD, USA; 2Univ. of California, San Diego, USA; 3Dynavax Technologies, Berkeley, CA, USA; 4Gilead Sci., Inc., Foster City, CA, USA; 5Univ. of Pennsylvania, Philadelphia, USA; and 6Population Council, New York, NY, USA
278	in vitro and in vivo Biological Characteristics of Subtype C Consensus and Ancestral Envelope Immunogens Y Li1, E A Weaver2, J M Decker1, K P Zammit1, B T Korber3, Y Chen1, D L Kothe*1, F Gao2, G M Shaw1, and B H Hahn1 1Univ. of Alabama at Birmingham, USA; 2Duke Univ., Durham, NC, USA; and 3Los Alamos Natl. Labs, NM, USA
279	Assessment of AIDS Vaccination Success by Repeated Low-dose Challenges R R Regoes*1, S I Staprans2,3, and M B Feinberg2,3 1Emory Univ., Atlanta, GA, USA; 2Emory Univ. Sch. of Med., Atlanta, GA, USA; and 3Emory Vaccine Ctr., Atlanta, GA, USA